I'm LongbridgeAI, I can summarize articles.William Blair analyst Sami Corwin has reiterated a Buy rating on Cabaletta Bio (CABA) due to strong non-preconditioned pemphigus vulgaris data, scalable manufacturing strategies, and multiple upcoming catalysts. He believes the company's clinical momentum and collaboration with Cellares will enhance value by lowering costs. Corwin's assessment highlights significant progress toward registrational pathways and upcoming data releases, justifying his bullish stance. Additionally, Guggenheim also maintained a Buy rating with a $16.00 price target.
William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating on May 5.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sami Corwin has given his Buy rating due to a combination of factors tied to Cabaletta Bio’s execution and clinical momentum. He views the latest pemphigus vulgaris data without preconditioning as particularly encouraging, arguing that comparable CAR T-cell expansion and clinical benefit versus preconditioned patients could set Cabaletta apart from other autoimmune competitors.
Corwin also highlights the company’s strategy and infrastructure as value drivers, citing the Cellares collaboration as a way to scale manufacturing while lowering per-dose costs. In his assessment, Cabaletta’s progress toward registrational pathways in multiple indications, along with upcoming data from RESET-SLE and RESET-SSc and additional higher-dose, non-preconditioned cohorts through 2026, offers a series of meaningful catalysts that justify a Buy rating on the stock.
According to TipRanks, Corwin is a 5-star analyst with an average return of 22.8% and a 59.23% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Tyra Bioscience, Cabaletta Bio, and Allogene Therapeutics.
In another report released on May 5, Guggenheim also reiterated a Buy rating on the stock with a $16.00 price target.